Back to top
more

MEI Pharma (MEIP)

(Delayed Data from NSDQ)

$3.25 USD

3.25
26,402

0.00 (0.00%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $3.30 +0.05 (1.54%) 6:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of -13.70% and 100%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer

AstraZeneca's (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer.

AstraZeneca's (AZN) Imfinzi Early-Stage Lung Cancer Study Fails

AstraZeneca's (AZN) PACIFIC-2 study on Imfinzi fails to achieve statistical significance for the primary endpoint of progression-free survival.

Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion

The FDA approves Pacira's (PCRX) supplemental new drug application to expand the label of Exparel to include both sciatic and femoral nerve blocks.

Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises

Ironwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line.

Amicus' (FOLD) Q3 Loss Narrows, Galafold Sales View Updated

Amicus (FOLD) incurs a narrower-than-expected loss in the third quarter. However, revenues beat estimates. The company tightens Galafold revenue guidance for 2023.

Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss

Nektar (NKTR) misses third-quarter estimates for the bottom line but beats the same for the top line.

Theravance's (TBPH) Q3 Loss Narrows, Revenues Beat Marginally

Thervance (TBPH) incurs a narrower-than-expected loss in the third quarter of 2023. Revenues marginally beat estimates.

Biogen (BIIB) Beats on Q3 Earnings & Sales, Cuts EPS View

Biogen (BIIB) beats third-quarter estimates for earnings and sales. It lowers its 2023 EPS guidance range to include the impact of dilution from the Reata acquisition. Stock rises in pre-market.

Axsome (AXSM) Q3 Loss Widens, Revenues Surpass Estimates

Axsome (AXSM) incurs a wider-than-expected loss in the third quarter of 2023 while sales beat estimates. The company's shares declined post earnings announcement.

Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised

Intra-Cellular (ITCI) third-quarter 2023 earnings and revenues beat estimates. Caplyta sales continue to drive growth. The company raises its guidance for full-year 2023 Caplyta sales.

ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues

ImmunoGen's (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong adoption of its sole-marketed drug Elahere. The company reiterates its revenue guidance.

Puma Biotech (PBYI) Q3 Earnings Beat, Revenues Lag Estimates

Puma Biotech's (PBYI) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens the full-year revenue guidance.

Zoetis' (ZTS) Q3 Earnings Beat, Revenues Miss by a Whisker

Zoetis' (ZTS) third-quarter 2023 earnings surpass estimates. However, revenues fall marginally short. The strong performance of the companion animal portfolio drives year-over-year revenues.

Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales View

Corcept's (CORT) third-quarter 2023 earnings and revenues surpass estimates. The company raises the full-year revenue guidance for 2023.

Apellis (APLS) Q3 Loss Wider Than Expected, Syfovre Drives Sales

Apellis' (APLS) third-quarter 2023 bottom line misses estimates, while the top line beats the same. Newly approved product, Syfovre, drives sales in the reported quarter.

Eli Lilly (LLY) Q3 Earnings & Sales Top, EPS View Cut, Stock Up

Eli Lilly (LLY) beats third-quarter estimates for earnings as well as sales. It cut its earnings guidance for 2023 on charges related to acquisitions and collaboration deals.

Amarin (AMRN) Q3 Earnings and Revenues Surpass Estimates

Amarin's (AMRN) third-quarter 2023 earnings and revenues beat estimates. Vascepa sales in the United States decline year over year.

Repligen (RGEN) Shares Rise on Q3 Earnings & Revenue Beat

Repligen's (RGEN) third-quarter earnings and revenues surpass estimates. The company tightens revenue guidance for 2023. Shares rise.

United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates

United Therapeutics (UTHR) third-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.

BEAM to Reprioritize Portfolio, Slash Jobs, Shares Tank

BEAM announces a restructuring and portfolio reprioritization plan to focus on genome-editing candidate, BEAM-101. The company is set to reduce its workforce by almost 20%. Shares fall.

Is it a Good Idea to Invest in Dynavax (DVAX) Stock Now?

Here, we discuss some reasons why investing in Dynavax Technologies (DVAX) stock now may turn out to be a prudent move.

Lisata's (LSTA) Lead Cancer Drug Gets EC's Orphan Tag, Stock Up

Lisata (LSTA) shares rise 6.6% after its lead candidate, LSTA1, receives orphan drug designation from the European Commission for treating pancreatic cancer.

Merck (MRK) Gets CHMP Nod for Expanded Use of Antiviral Drug

CHMP gives a positive opinion to Merck (MRK) for the expanded use of Prevymis to help prevent CMV disease in high-risk kidney transplant patients.

J&J (JNJ) Beats Q3 Earnings & Sales Estimates Post Spin-Off

J&J (JNJ) beats estimates for third-quarter earnings and sales. It raises full-year sales and earnings guidance.